412 completed, 96 terminated, 61 unknown, 59 recruiting. 387 Phase 2, 184 Phase 1, 131 Phase 3, 40 Not applicable, 31 Phase 4.
Follow this drug Literature Review of Granulocyte Colony-Stimulating Factor trials Research Report on Granulocyte Colony-Stimulating Factor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | University of California, Davis | 20 | 2026-09-01 | 2026-08-12 |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF - R/R AML | Phase 2 | Active not recruiting | Liping Dou | 32 | 2026-07-30 | 2026-10-15 |
| Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors Single-dose Granulocyte colony-stimulating factor (G-CSF), Divided-dose Granulocyte colony-stimulating factor (G-CSF) - Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 560 | 2026-07-10 | 2026-07-15 |
| Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer Sacituzumab Govitecan (SG), Atropine, G-CSF (Granulocyte colony-stimulating factor) - Breast Cancer, Advanced HR+/HER2- Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 30 | 2026-07-01 | 2026-01-28 |
| A-TANGO Phase 2 Study Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis | Phase 2 | Recruiting | Yaqrit Ltd | 78 | 2026-06-29 | 2026-09-21 |
| A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) Ris-Rez, G-CSF - Sarcoma | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 64 | 2026-06-22 | 2026-10-01 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-19 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib, Cyclophosphamide, Etoposide - High Grade Glioma, CNS Tumor | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 52 | 2026-05-01 | 2026-05-13 |
| A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia Fludarabine, Cytarabine, G-CSF - Phase I, FLAG Chemotherapy | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-04-27 | 2026-05-07 | |
| VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF - AML (Acute Myeloid Leukemia) | Phase 2 | Recruiting | Beijing 302 Hospital | 48 | 2026-04-15 | 2026-04-07 |
| Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) Intervention for Venetoclax, Intervention for Homoharringtonine, Intervention for Azacitidine - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | First People's Hospital of Hangzhou | 61 | 2026-03-31 | 2026-04-02 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors G-CSF (Granulocyte colony-stimulating factor) - Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 160 | 2026-03-01 | 2026-06-29 |
| The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation Thiotepa, Fludarabine, G-CSF - Hematologic Malignancies | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2026-02-20 | 2026-03-02 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-12-16 | 2026-06-05 |
| Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus Sirolimus, Busulfan, Horse -Anti-thymocyte - Severe Combined Immune Deficiency (SCID) | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-11-26 | 2025-12-01 | |
| Mozobil for Autologous Hematopoietic Stem Cell Transplantation Plerixafor, Gcsf - Multiple Myeloma, Hodgkin Lymphoma | Phase 2 | Recruiting | Thomas Jefferson University | 100 | 2025-10-16 | 2025-11-28 |
Showing 20 of 703. Sign in to see all of them.
Leukemia, Myeloid, Acute (124) · Multiple Myeloma (85) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (76) · Lymphoma (73) · Leukemia (66) · Lymphoma, Non-Hodgkin (66) · Myelodysplastic Syndromes (64) · Hodgkin Disease (53) · Lymphoma, Large B-Cell, Diffuse (37) · Lymphoma, Mantle-Cell (33) · Breast Neoplasms (32) · Burkitt Lymphoma (30) · Leukemia, Lymphocytic, Chronic, B-Cell (30) · Neuroblastoma (30) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (26)
M.D. Anderson Cancer Center (71) · Children's Oncology Group (60) · National Cancer Institute (NCI) (44) · Masonic Cancer Center, University of Minnesota (25) · St. Jude Children's Research Hospital (23) · Washington University School of Medicine (18) · Fred Hutchinson Cancer Center (16) · University of Washington (15) · Genzyme, a Sanofi Company (14) · City of Hope Medical Center (12) · Northwestern University (12) · Alliance for Clinical Trials in Oncology (9) · National Heart, Lung, and Blood Institute (NHLBI) (9) · Stanford University (9) · Emory University (6)
United States (505) · Canada (78) · Australia (57) · China (51) · Puerto Rico (32) · Germany (30) · Switzerland (27) · Spain (25) · France (23) · New Zealand (20) · Italy (18) · Netherlands (18) · United Kingdom (18) · India (16) · South Korea (15)
Richard Burt, MD (11) · Brandon Triplett, MD (6) · Dieter Hoelzer, MD,PhD (4) · Ashish Gupta, MBBS, MPH (3) · Dimitris Mavrudis, MD (3) · Issa F. Khouri, MD,BS (3) · Pamela Becker (3) · Richard E. Champlin, MD (3) · Wen-Kai Weng (3) · Amar Gajjar, MD (2) · Anna Halpern (2)
PMID 37505794, PMID 19144982, PMID 22442346, PMID 22493293, PMID 22965967, PMID 23024237, PMID 27561722, PMID 28751559, PMID 29410180, PMID 33242441, PMID 33735476, PMID 34515338, PMID 35391541, PMID 36184192, PMID 36240296, PMID 37035316, PMID 40135712, PMID 42668697, PMID 10820362, PMID 15659500, PMID 15814645, PMID 16192477, PMID 16547940, PMID 16818281, PMID 16943538, PMID 17132719, PMID 17138821, PMID 17312330, PMID 17439836, PMID 18256325, PMID 18371107, PMID 18493992, PMID 18759768, PMID 18985718, PMID 18997171, PMID 19020548, PMID 19021050, PMID 19064966, PMID 19135941, PMID 19167685, PMID 19179301, PMID 19224841, PMID 19242495, PMID 19289999, PMID 19304957, PMID 19363221, PMID 19423725, PMID 19443658, PMID 19483760, PMID 19546405
U10CA098543 (29), U10CA180886 (14), P30CA016672 (12), U10CA031946 (12), P30CA015704 (9), U10CA027469 (8), U10CA032102 (8), U10CA021115 (7), P30CA033572 (5), 2014 (4), P01CA081403 (4), 2005 (3), 2018 (3), P30CA006973 (3), U01CA097452 (3)